Hemogenyx Pharmaceuticals innovates brain cancer treatment with CBR delivery
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by demonstrating the ability to deliver its proprietary ... Read More
Hemogenyx Pharmaceuticals innovates with intranasal mRNA delivery for airborne viral infections
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant stride in the realm of biotechnology with its recent in vivo demonstration ... Read More
Hemogenyx Pharmaceuticals receives FDA nod for HEMO-CAR-T AML treatment study
Hemogenyx Pharmaceuticals plc, a London-based biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its Phase I clinical ... Read More